BioCentury | Jul 19, 2019
Financial News

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

Ahead of Vascepa push, Amarin adds $400M to coffers With the Sept. 28 PDUFA date looming for a potential expansion of the label for Vascepa icosapent to include reduced cardiovascular risk, Amarin Corp. plc (NASDAQ:AMRN)...
BioCentury | Nov 9, 2015
Clinical News

Fispemifene: Completed Phase IIb enrollment

Apricus completed enrollment of 161 patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating 450 mg oral fispemifene once daily for 8 weeks. Apricus has exclusive, U.S. rights to the product from Forendo (see...
BioCentury | Oct 27, 2014
Financial News

Forendo Pharma completes venture financing

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Date completed: 2014-10-22 Type: Venture financing Raised: EUR3 million ($3.8 million) Investors: Novartis Venture Funds; MS Ventures; Karolinska Development AB ; Novo Seeds; Finnvera Venture Capital Note:...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma, Apricus Biosciences deal

Forendo granted Apricus exclusive, U.S. rights to develop and commercialize fispemifene , which has completed two Phase II trials for male secondary hypogonadism. Forendo received an upfront license fee of $12.5 million, consisting of $5 million...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma board of directors update

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Appointed: Hakan Goker, an investment director at MS Ventures; and Anja Konig, managing director at Novartis Venture Fund WIR Staff Genitourinary...
BioCentury | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB ; Novo Seeds; and...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

Forendo Pharma Oy is developing inhibitors of hydroxysteroid 17-beta dehydrogenase 1 to treat endometriosis without depleting circulating estrogen, thus avoiding side effects of available therapies. In endometriosis, tissue similar to endometrium in the uterus grows...
BioCentury | Jul 1, 2013
Financial News

Forendo Pharma completes venture financing

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Date completed: 6/25/13 Type: Venture financing Raised: €3.5 million ($4.6 million) Investors: Karolinska Development AB ; Novo Seeds; Finnvera Venture Capital Note: The company raised €3.5 million...
Items per page:
1 - 8 of 8
BioCentury | Jul 19, 2019
Financial News

July 19 Financial Quick Takes: Amarin raises cash ahead of Vascepa PDUFA date, plus Atara, Sunstone and Forendo

Ahead of Vascepa push, Amarin adds $400M to coffers With the Sept. 28 PDUFA date looming for a potential expansion of the label for Vascepa icosapent to include reduced cardiovascular risk, Amarin Corp. plc (NASDAQ:AMRN)...
BioCentury | Nov 9, 2015
Clinical News

Fispemifene: Completed Phase IIb enrollment

Apricus completed enrollment of 161 patients in a double-blind, placebo-controlled, U.S. Phase IIb trial evaluating 450 mg oral fispemifene once daily for 8 weeks. Apricus has exclusive, U.S. rights to the product from Forendo (see...
BioCentury | Oct 27, 2014
Financial News

Forendo Pharma completes venture financing

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Date completed: 2014-10-22 Type: Venture financing Raised: EUR3 million ($3.8 million) Investors: Novartis Venture Funds; MS Ventures; Karolinska Development AB ; Novo Seeds; Finnvera Venture Capital Note:...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma, Apricus Biosciences deal

Forendo granted Apricus exclusive, U.S. rights to develop and commercialize fispemifene , which has completed two Phase II trials for male secondary hypogonadism. Forendo received an upfront license fee of $12.5 million, consisting of $5 million...
BioCentury | Oct 27, 2014
Company News

Forendo Pharma board of directors update

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Appointed: Hakan Goker, an investment director at MS Ventures; and Anja Konig, managing director at Novartis Venture Fund WIR Staff Genitourinary...
BioCentury | Oct 23, 2014
Financial News

Forendo closes EUR 12M series A

Forendo Pharma Oy (Turku, Finland) closed a EUR 12 million ($15.3 million) series A round led by new investors Novartis Venture Fund and MS Ventures. Existing investors including Karolinska Development AB ; Novo Seeds; and...
BioCentury | Oct 14, 2013
Emerging Company Profile

Forendo: Fixing endometriosis

Forendo Pharma Oy is developing inhibitors of hydroxysteroid 17-beta dehydrogenase 1 to treat endometriosis without depleting circulating estrogen, thus avoiding side effects of available therapies. In endometriosis, tissue similar to endometrium in the uterus grows...
BioCentury | Jul 1, 2013
Financial News

Forendo Pharma completes venture financing

Forendo Pharma Oy , Turku, Finland Business: Genitourinary, Endocrine/Metabolic Date completed: 6/25/13 Type: Venture financing Raised: €3.5 million ($4.6 million) Investors: Karolinska Development AB ; Novo Seeds; Finnvera Venture Capital Note: The company raised €3.5 million...
Items per page:
1 - 8 of 8